Wilshire enhances investment suite with acquisition of Lyxor U.S.

TAGS

Wilshire, a prominent global financial services firm, has successfully completed its acquisition of Lyxor Asset Management Inc. (“Lyxor U.S.”), significantly bolstering its position in the financial sector. This move integrates Lyxor U.S., a U.S.-based investment advisor business with $20.8 billion in assets under management, into Wilshire’s extensive portfolio.

This strategic acquisition is a fusion of two firms with a shared vision of improving investment outcomes for their clients. By incorporating Lyxor U.S., Wilshire enhances its range of investment products and establishes a leading position in the alternatives platform, broadening the spectrum of investment opportunities available to clients of both legacy entities.

See also  Advanced Marine Corps F-35B fighter jet vanishes in South Carolina mishap

The transaction, first announced on October 31, 2023, signifies Wilshire’s transition into a leading provider of hedge fund managed accounts and boosts its offerings in alternative investments. The acquisition of Lyxor U.S., previously a wholly-owned subsidiary of Amundi Holdings US, Inc. and part of the major European ETF and liquid alternatives provider Lyxor, acquired by Amundi in 2021, reinforces Wilshire’s capabilities in alternatives, particularly through hedge fund managed accounts, and brings Lyxor U.S.’s esteemed institutional client base into Wilshire’s ecosystem.

Wilshire Completes Acquisition of Lyxor Asset Management, Expanding Financial Horizons

Wilshire Completes Acquisition of Lyxor Asset Management, Expanding Financial Horizons

Meanwhile, Amundi, the largest European asset manager, will continue to focus on growing its asset management and distribution capabilities in the Americas, including through Amundi US, a presence it has maintained since 1928. Amundi also reaffirms its commitment to expanding its liquid alternatives business globally outside the U.S.

See also  Enova International acquires payments platform Pangea Universal

The acquisition is a Class 2 transaction for Wilshire according to the UK Financial Conduct Authority’s Listing Rules. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, emphasized the operational and commercial synergies expected from this acquisition, looking forward to realizing these benefits in 2024 and beyond.

This acquisition represents a significant step in the consolidation and expansion of the global financial services industry, indicating Wilshire’s commitment to enhancing its position as a quality and innovation-led financial service provider.

CATEGORIES
TAGS
Share This